NTCI cSN50.1 peptide (Vanderbilt University) Researchers at Vanderbilt University Medical Center developed a topical peptide drug that controls 15 genes responsible for the painful inflammation in atopic dermatitis
doi: 10.3390/ijms222413205
Most users report reduced inflammation and improved recovery within 2 to 3 weeks
Since IDPs have a range of flexible, unfolded conformations, this ability to measure different protein shapes was critical for their subsequent characterization by this technique
GHK could form the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu 2+ (GHK-Cu) by the good affinity for Cu(II), which proved to exhibit good antioxidant and anti-inflammatory capabilities (Pickart, 2008)
Monitoring strategies include periodic assessment of treatment response, adjustment of protocols based on outcomes, and long-term maintenance planning